Genmab Geared Up To Launch Epkinly With AbbVie
As FDA Approves CD20xCD3 Bispecific For Lymphoma
The Danish group, along with partner AbbVie, is all set for a commercial battle with Roche as Epkinly hits the US market for refractory diffuse large B-cell lymphoma a few weeks ahead of expected approval for the Swiss major’s same-in-class rival glofitamab.
You may also be interested in...
The companies unveiled results showing a high overall response rate from the anti-CD20xCD3 bispecific as competition heats up between various players in the space.
The company is touting the drug’s fixed-duration treatment as an advantage for patients, while the new drug class has ignited discussion around their use in the community oncology setting.
GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.